Therapeutic Effect of the Endogenous Fatty Acid Amide, Palmitoylethanolamide, in Rat Acute Inflammation: Inhibition of Nitric Oxide and Cyclo-oxygenase Systems
Overview
Affiliations
1. The anti-inflammatory activity of the endogenous fatty acid amide palmitoylethanolamide and its relationship to cyclo-oxygenase (COX) activity, nitric oxide (NO) and oxygen free radical production were investigated in the rat model of carrageenan-induced acute paw inflammation and compared with the nonsteroidal anti-inflammatory drug (NSAID) indomethacin. 2. Palmitoylethanolamide (1, 3, 5, 10 mg kg(-1); p.o.) and indomethacin (5 mg kg(-1); p.o.) were administered daily after the onset of inflammation for three days and the paw oedema was measured daily; 24 h after the last dose (fourth day) the rats were killed and the COX activity and the content of nitrite/nitrate (NO(2)(-)/NO(3)(-)), malondialdehyde (MDA), endothelial and inducible nitric oxide synthase (eNOS and iNOS) were evaluated in the paw tissues. 3. Palmitoylethanolamide had a curative effect on inflammation, inhibiting the carrageenan-induced oedema in a dose- and time-dependent manner. This effect was not reversed by the selective CB(2) receptor antagonist (N-[(1S)-endo-1,3,3-trimethylbicyclo[2.2.1]heptan-2yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)pyrazole-3 carboxamide) (SR144528), 3 mg kg(-1) p.o. On the fourth day after carrageenan injection, COX activity and the level of NO(2)(-)/NO(3)(-), eNOS and MDA were increased in the inflamed paw, but iNOS was not present. Palmitoylethanolamide (10 mg kg(-1)) and indomethacin markedly reduced these increases. 4. Our findings show, for the first time, that palmitoylethanolamide has a curative effect in a model of acute inflammation. The inhibition of COX activity and of NO and free radical production at the site of inflammation might account for this activity.
Palmitoylethanolamide causes dose-dependent changes in brain function and the lipidome.
Balaji S, Woodward T, Richter E, Chang A, Otiz R, Kulkarni P Front Neurosci. 2024; 18:1506352.
PMID: 39664446 PMC: 11631868. DOI: 10.3389/fnins.2024.1506352.
Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.
Ramer R, Hinz B Cells. 2022; 11(24).
PMID: 36552866 PMC: 9777118. DOI: 10.3390/cells11244102.
Sanchez-Sanz A, Posada-Ayala M, Sabin-Munoz J, Fernandez-Miranda I, Aladro-Benito Y, Alvarez-Lafuente R Sci Rep. 2022; 12(1):20300.
PMID: 36434122 PMC: 9700785. DOI: 10.1038/s41598-022-21807-y.
Bellanti F, Naik Bukke V, Moola A, Villani R, Scuderi C, Steardo L Front Aging Neurosci. 2022; 14:890855.
PMID: 35686025 PMC: 9170916. DOI: 10.3389/fnagi.2022.890855.
Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans.
Landolfo E, Cutuli D, Petrosini L, Caltagirone C Biomolecules. 2022; 12(5).
PMID: 35625595 PMC: 9138306. DOI: 10.3390/biom12050667.